Latest Breaking News On - ர சி து லண்ட்பெர்க் - Page 1 : comparemela.com
Merus N V : Merus Announces Financial Results for the Second Quarter and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Merus N V : Merus to Participate in William Blair s Biotech Focus Conference 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Merus to Participate in William Blair s Biotech Focus Conference 2021
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Merus N.V.: Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference and Triclonics
), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET.
The live webcast of the presentation will be available on the Investors page of the Company s website. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics
(1)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.
The live webcast of the presentation will be available on the Investors page of the Company s website. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half